Nucynta ER

See also: Generic Nucynta

Nucynta ER is a brand name of tapentadol, approved by the FDA in the following formulation(s):

NUCYNTA ER (tapentadol hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: August 25, 2011
  
  Strength(s): EQ 100MG BASE, EQ 150MG BASE, EQ 200MG BASE, EQ 250MG BASE ^[RLD], EQ 50MG BASE
  

Has a generic version of Nucynta ER been approved?

No. There is currently no therapeutically equivalent version of Nucynta ER available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nucynta ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
  Patent 6,071,970
  Issued: June 6, 2000
  Inventor(s): Mueller; Alan L. & Balandrin; Manuel F. & VanWagenen; Bradford C. & DelMar; Eric G. & Moe; Scott T. & Artman; Linda D. & Barmore; Robert M.
  Assignee(s): NPS Pharmaceuticals, Inc.
  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
  
  Patent expiration dates:
  
  
  • June 6, 2017
    
    ✓ 
    Patent use: RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
  
  



• 
  Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
  Patent 7,994,364
  Issued: August 9, 2011
  Inventor(s): Fischer; Andreas & Buschmann; Helmut & Gruss; Michael & Lischke; Dagmar
  Assignee(s): Gruenenthal GmbH
  A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
  
  Patent expiration dates:
  
  
  • June 27, 2025
    
    ✓ 
    Patent use: RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Abuse-proofed dosage form
  Patent 8,075,872
  Issued: December 13, 2011
  Inventor(s): Arkenau-Maric; Elisabeth & Bartholomäus; Johannes & Kugelmann; Heinrich
  Assignee(s): Gruenenthal GmbH
  The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.
  
  Patent expiration dates:
  
  
  • November 20, 2023
    
    ✓ 
    Drug product
  
  



• 
  1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
  Patent RE39593
  Issued: April 24, 2007
  Inventor(s): Buschmann; Helmut & Strassburger; Wolfgang & Friderichs; Elmar
  Assignee(s): Gruenenthal GmbH
  1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.
  
  Patent expiration dates:
  
  
  • August 5, 2022
    
    ✓ 
    Patent use: RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 20, 2013 - NEW CHEMICAL ENTITY
  
  
  • August 25, 2014 - NEW DOSAGE FORM
  
  

See also...

• Nucynta ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Nucynta ER Consumer Information (Cerner Multum)
• Nucynta ER Advanced Consumer Information (Micromedex)
• Tapentadol Consumer Information (Drugs.com)
• Tapentadol Consumer Information (Wolters Kluwer)
• Tapentadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Tapentadol Consumer Information (Cerner Multum)
• Tapentadol Advanced Consumer Information (Micromedex)
• Tapentadol Hydrochloride AHFS DI Monographs (ASHP)